FDA 483 - Cell Therapeutics Inc - November 18, 2009

An FDA inspection of Cell Therapeutics Inc in Seattle, WA, revealed a significant lapse in regulatory reporting for clinical trials. The firm failed to notify the FDA about the termination, for cause, of an investigator's participation in a clinical study. This indicates a deficiency in the firm's oversight and compliance with clinical investigation regulations.